Multitarget Strategies to Reduce Myocardial Ischemia/Reperfusion Injury: JACC Review Topic of the Week

Journal of the American College of Cardiology

Volumn 73, Issue 1, 2019, Pages 89-99

  Davidson, Sean M ^a   Ferdinandy, Péter ^b,c   Andreadou, Ioanna ^d   Bøtker, Hans Erik ^e   Heusch, Gerd ^f   Ibáñez, Borja ^g,h,i   Ovize, Michel ^j   Schulz, Rainer ^k   Yellon, Derek M ^a   Hausenloy, Derek J ^a,l,m,n,o   Garcia Dorado, David ^i,p,q  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c PHARMAHUNGARY GROUP   (Hungary)

^d UNIVERSITY OF ATHENS   (Greece)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^h CIBER de Enfermedades CardioVasculares ^*  (Spain)

ⁱ HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^j UNIVERSITÉ DE LYON   (France)

^k JUSTUS LIEBIG UNIVERSITY   (Germany)

^l DUKE NUS MEDICAL SCHOOL   (Singapore)

^m DEPARTMENT OF CARDIOLOGY   (Singapore)

ⁿ NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^o SCHOOL OF ENGINEERING AND SCIENCES   (Mexico)

^p HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^q UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

more..

Author keywords

cardioprotection; ischemia; myocardial infarction; reperfusion

Indexed keywords

BELNACASAN; CANGRELOR; CARIPORIDE; EXENDIN 4; TICAGRELOR;

ACUTE HEART INFARCTION; CARDIAC MUSCLE CELL; COMORBIDITY; DRUG TARGETING; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART PROTECTION; HUMAN; INDUCED HYPOTHERMIA; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NERVE STIMULATION; NONHUMAN; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PATHOLOGY;

HUMANS; MYOCARDIAL REPERFUSION INJURY;

EID: 85059103889     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.09.086     Document Type: Review

References (64)

1. Heusch, G., Critical issues for the translation of cardioprotection. Circ Res 120 (2017), 1477–1486.
2. Heusch, G., Cardioprotection research must leave its comfort zone. Eur Heart J 39 (2018), 3393–3395.
3. Hausenloy, D.J., Botker, H.E., Engstrom, T., et al. Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations. Eur Heart J 38 (2017), 935–941.
4. Heusch, G., Gersh, B.J., The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. Eur Heart J 38 (2017), 774–784.
5. Ferdinandy, P., Hausenloy, D.J., Heusch, G., Baxter, G.F., Schulz, R., Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev 66 (2014), 1142–1174.
6. Hausenloy, D.J., Garcia-Dorado, D., Botker, H.E., et al. Novel targets and future strategies for acute cardioprotection: position paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovasc Res 113 (2017), 564–585.
7. Inserte, J., Hernando, V., Vilardosa, U., Abad, E., Poncelas-Nozal, M., Garcia-Dorado, D., Activation of cGMP/protein kinase G pathway in postconditioned myocardium depends on reduced oxidative stress and preserved endothelial nitric oxide synthase coupling. J Am Heart Assoc, 2, 2013, e005975.
8. Alburquerque-Bejar, J.J., Barba, I., Inserte, J., et al. Combination therapy with remote ischaemic conditioning and insulin or exenatide enhances infarct size limitation in pigs. Cardiovasc Res 107 (2015), 246–254.
9. Kleinbongard, P., Skyschally, A., Heusch, G., Cardioprotection by remote ischemic conditioning and its signal transduction. Pflugers Arch 469 (2017), 159–181.
10. Heusch, G., Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res 116 (2015), 674–699.
11. Ruiz-Meana, M., Garcia-Dorado, D., Pina, P., Inserte, J., Agullo, L., Soler-Soler, J., Cariporide preserves mitochondrial proton gradient and delays ATP depletion in cardiomyocytes during ischemic conditions. Am J Physiol Heart Circ Physiol 285 (2003), H999–H1006.
12. Miki, T., Liu, G.S., Cohen, M.V., Downey, J.M., Mild hypothermia reduces infarct size in the beating rabbit heart: a practical intervention for acute myocardial infarction?. Basic Res Cardiol 93 (1998), 372–383.
13. Ibanez, B., Macaya, C., Sanchez-Brunete, V., et al. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial. Circulation 128 (2013), 1495–1503.
14. Selker, H.P., Beshansky, J.R., Sheehan, P.R., et al. Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. JAMA 307 (2012), 1925–1933.
15. Botker, H.E., Kharbanda, R., Schmidt, M.R., et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 375 (2010), 727–734.
16. Kleinbongard, P., Amanakis, G., Skyschally, A., Heusch, G., Reflection of cardioprotection by remote ischemic perconditioning in attenuated ST-segment elevation during ongoing coronary occlusion in pigs: evidence for cardioprotection from ischemic injury. Circ Res 122 (2018), 1102–1108.
17. Garcia-Ruiz, J.M., Fernandez-Jimenez, R., Garcia-Alvarez, A., et al. Impact of the timing of metoprolol administration during STEMI on infarct size and ventricular function. J Am Coll Cardiol 67 (2016), 2093–2104.
18. Ovize, M., Baxter, G.F., Di Lisa, F., et al. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 87 (2010), 406–423.
19. Hausenloy, D.J., Duchen, M.R., Yellon, D.M., Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res 60 (2003), 617–625.
20. Kin, H., Zhao, Z.Q., Sun, H.Y., et al. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res 62 (2004), 74–85.
21. Doukas, J., Wrasidlo, W., Noronha, G., et al. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc Natl Acad Sci U S A 103 (2006), 19866–19871.
22. Souktani, R., Pons, S., Guegan, C., et al. Cardioprotection against myocardial infarction with PTD-BIR3/RING, a XIAP mimicking protein. J Mol Cell Cardiol 46 (2009), 713–718.
23. Basalay, M., Barsukevich, V., Mastitskaya, S., et al. Remote ischaemic pre- and delayed postconditioning - similar degree of cardioprotection but distinct mechanisms. Exp Physiol 97 (2012), 908–917.
24. Hausenloy, D.J., Yellon, D.M., Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest 123 (2013), 92–100.
25. Figueras, J., Otaegui, I., Marti, G., et al. Area at risk and collateral circulation in a first acute myocardial infarction with occluded culprit artery. STEMI vs non-STEMI patients. Int J Cardiol 259 (2018), 14–19.
26. Ibanez, B., James, S., Agewall, S., et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39 (2018), 119–177.
27. Garcia-Prieto, J., Villena-Gutierrez, R., Gomez, M., et al. Neutrophil stunning by metoprolol reduces infarct size. Nat Commun, 8, 2017, 14780.
28. Abrial, M., Da Silva, C.C., Pillot, B., et al. Cardiac fibroblasts protect cardiomyocytes against lethal ischemia-reperfusion injury. J Mol Cell Cardiol 68 (2014), 56–65.
29. Giricz, Z., Varga, Z.V., Baranyai, T., et al. Cardioprotection by remote ischemic preconditioning of the rat heart is mediated by extracellular vesicles. J Mol Cell Cardiol 68 (2014), 75–78.
30. Jose Corbalan, J., Vatner, D.E., Vatner, S.F., Myocardial apoptosis in heart disease: does the emperor have clothes?. Basic Res Cardiol, 111, 2016, 31.
31. Garcia-Dorado, D., Andres-Villarreal, M., Ruiz-Meana, M., Inserte, J., Barba, I., Myocardial edema: a translational view. J Mol Cell Cardiol 52 (2012), 931–939.
32. Heusch, G., The coronary circulation as a target of cardioprotection. Circ Res 118 (2016), 1643–1658.
33. Russo, I., Penna, C., Musso, T., et al. Platelets, diabetes and myocardial ischemia/reperfusion injury. Cardiovasc Diabetol, 16, 2017, 71.
34. Barrabes, J.A., Inserte, J., Mirabet, M., et al. Antagonism of P2Y12 or GPIIb/IIIa receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat hearts. Thromb Haemost 104 (2010), 128–135.
35. Vilahur, G., Gutierrez, M., Casani, L., et al. Protective effects of ticagrelor on myocardial injury after infarction. Circulation 134 (2016), 1708–1719.
36. Fernandez-Jimenez, R., Barreiro-Perez, M., Martin-Garcia, A., et al. Dynamic edematous response of the human heart to myocardial infarction: implications for assessing myocardial area at risk and salvage. Circulation 136 (2017), 1288–1300.
37. Garcia-Dorado, D., Theroux, P., Solares, J., et al. Determinants of hemorrhagic infarcts. Histologic observations from experiments involving coronary occlusion, coronary reperfusion, and reocclusion. Am J Pathol 137 (1990), 301–311.
38. Heusch, G., Kleinbongard, P., Bose, D., et al. Coronary microembolization: from bedside to bench and back to bedside. Circulation 120 (2009), 1822–1836.
39. Rossello, X., Yellon, D.M., The RISK pathway and beyond. Basic Res Cardiol, 113, 2017, 2.
40. Cohen, M.V., Downey, J.M., The impact of irreproducibility and competing protection from P2Y12 antagonists on the discovery of cardioprotective interventions. Basic Res Cardiol, 112, 2017, 64.
41. Audia, J.P., Yang, X.-M., Crockett, E.S., et al. Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y12 receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function. Basic Res Cardiol, 113, 2018.
42. Koshinuma, S., Miyamae, M., Kaneda, K., Kotani, J., Figueredo, V.M., Combination of necroptosis and apoptosis inhibition enhances cardioprotection against myocardial ischemia-reperfusion injury. J Anesth 28 (2014), 235–241.
43. Galaup, A., Gomez, E., Souktani, R., et al. Protection against myocardial infarction and no-reflow through preservation of vascular integrity by angiopoietin-like 4. Circulation 125 (2012), 140–149.
44. Yang, X.M., Cui, L., Alhammouri, A., Downey, J.M., Cohen, M.V., Triple therapy greatly increases myocardial salvage during ischemia/reperfusion in the in situ rat heart. Cardiovasc Drugs Ther 27 (2013), 403–412.
45. Lux, A., Pokreisz, P., Swinnen, M., et al. Concomitant phosphodiesterase 5 inhibition enhances myocardial protection by inhaled nitric oxide in ischemia-reperfusion injury. J Pharmacol Exp Ther 356 (2016), 284–292.
46. Tratsiakovich, Y., Gonon, A.T., Kiss, A., et al. Myocardial protection by co-administration of L-arginine and tetrahydrobiopterin during ischemia and reperfusion. Int J Cardiol 169 (2013), 83–88.
47. Lougiakis, N., Papapetropoulos, A., Gikas, E., et al. Synthesis and pharmacological evaluation of novel adenine-hydrogen sulfide slow release hybrids designed as multitarget cardioprotective agents. J Med Chem 59 (2016), 1776–1790.
48. Rastaldo, R., Cappello, S., Di Stilo, A., Folino, A., Losano, G., Pagliaro, P., A lipophilic nitric oxide donor and a lipophilic antioxidant compound protect rat heart against ischemia-reperfusion injury if given as hybrid molecule but not as a mixture. J Cardiovasc Pharmacol 59 (2012), 241–248.
49. Tsang, A., Hausenloy, D.J., Mocanu, M.M., Carr, R.D., Yellon, D.M., Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes 54 (2005), 2360–2364.
50. Xue, R., Lei, S., Xia, Z.Y., et al. Selective inhibition of PTEN preserves ischaemic post-conditioning cardioprotection in STZ-induced Type 1 diabetic rats: role of the PI3K/Akt and JAK2/STAT3 pathways. Clin Sci (Lond) 130 (2016), 377–392.
51. Fan, Y., Yang, S., Zhang, X., Cao, Y., Huang, Y., Comparison of cardioprotective efficacy resulting from a combination of atorvastatin and ischaemic post-conditioning in diabetic and non-diabetic rats. Clin Exp Pharmacol Physiol 39 (2012), 938–943.
52. Cung, T.T., Morel, O., Cayla, G., et al. Cyclosporine before PCI in patients with acute myocardial infarction. N Engl J Med 373 (2015), 1021–1031.
53. Lonborg, J., Vejlstrup, N., Kelbaek, H., et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 33 (2012), 1491–1499.
54. Eitel, I., Stiermaier, T., Rommel, K.P., et al. Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction: the randomized LIPSIA CONDITIONING trial. Eur Heart J 36 (2015), 3049–3057.
55. Prunier, F., Angoulvant, D., Saint Etienne, C., et al. The RIPOST-MI study, assessing remote ischemic perconditioning alone or in combination with local ischemic postconditioning in ST-segment elevation myocardial infarction. Basic Res Cardiol, 109, 2014, 400.
56. Pasupathy, S., Tavella, R., Grover, S., et al. Early use of N-acetylcysteine with nitrate therapy in patients undergoing primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction reduces myocardial infarct size (the NACIAM Trial [N-acetylcysteine in Acute Myocardial Infarction]). Circulation 136 (2017), 894–903.
57. Roolvink, V., Ibanez, B., Ottervanger, J.P., et al. Early intravenous beta-blockers in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary intervention. J Am Coll Cardiol 67 (2016), 2705–2715.
58. Schwiebert, C., Huhn, R., Heinen, A., et al. Postconditioning by xenon and hypothermia in the rat heart in vivo. Eur J Anaesthesiol 27 (2010), 734–739.
59. Sun, J., Aponte, A.M., Menazza, S., Gucek, M., Steenbergen, C., Murphy, E., Additive cardioprotection by pharmacological postconditioning with hydrogen sulfide and nitric oxide donors in mouse heart: S-sulfhydration vs. S-nitrosylation. Cardiovasc Res 110 (2016), 96–106.
60. Yang, X.M., Cui, L., White, J., et al. Mitochondrially targeted Endonuclease III has a powerful anti-infarct effect in an in vivo rat model of myocardial ischemia/reperfusion. Basic Res Cardiol, 110, 2015, 3.
61. Alexopoulos, P., Panoutsopoulou, K., Vogiatzis, G., Koletsis, E., Dougenis, D., Tsopanoglou, N.E., Combined treatment with exenatide and cyclosporine A or parstatin 1-26 results in enhanced reduction of infarct size in a rabbit model. J Cardiovasc Pharmacol 70 (2017), 34–41.
62. Xin, P., Zhu, W., Ma, S., et al. Combined local ischemic postconditioning and remote perconditioning recapitulate cardioprotective effects of local ischemic preconditioning. Am J Physiol Heart Circ Physiol 298 (2010), H1819–H1831.
63. Huang, M.H., Wu, Y., Nguyen, V., et al. Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion. Cardiovasc Drugs Ther 25 (2011), 223–232.
64. Wang, Q., Liu, G.P., Xue, F.S., et al. Combined vagal stimulation and limb remote ischemic perconditioning enhances cardioprotection via an anti-inflammatory pathway. Inflammation 38 (2015), 1748–1760.